Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Niraparib
Accession Number
DB11793
Type
Small Molecule
Groups
Approved, Investigational
Description

Niraparib is an orally active PARP inhibitor developed by Tesaro to treat ovarian cancer. FDA approval on March 2017.

Structure
Thumb
Synonyms
  • Niraparib
External IDs
MK 4827 / MK-4827 / MK-4827 FREE BASE / MK4827
Product Ingredients
IngredientUNIICASInChI Key
Niraparib hydrochlorideL4JFC1PHCI1038915-64-8YXYDNYFWAFBCAN-PFEQFJNWSA-N
Niraparib tosylate75KE12AY9U1038915-73-9LCPFHXWLJMNKNC-PFEQFJNWSA-N
Niraparib tosylate monohydrate195Q483UZD1613220-15-7ACNPUCQQZDAPJH-FMOMHUKBSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ZejulaCapsule100 mgOralGlaxosmithkline IncNot applicableNot applicableCanada
ZejulaCapsule100 mg/1OralTesaro, Inc.2017-03-27Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Categories
UNII
HMC2H89N35
CAS number
1038915-60-4
Weight
Average: 320.396
Monoisotopic: 320.16371128
Chemical Formula
C19H20N4O
InChI Key
PCHKPVIQAHNQLW-CQSZACIVSA-N
InChI
InChI=1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1
IUPAC Name
2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
SMILES
NC(=O)C1=CC=CC2=CN(N=C12)C1=CC=C(C=C1)[C@@H]1CCCNC1

Pharmacology

Indication

Niraparib is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy

Associated Conditions
Pharmacodynamics

Cardiovascular Effects: Niraparib has the potential to cause effects on pulse rate and blood pressure in patients receiving the recommended dose, which may be related to pharmacological inhibition of the dopamine transporter (DAT), norepinephrine transporter (NET) and serotonin transporter (SERT). In the NOVA study, mean pulse rate and blood pressure increased over baseline in the niraparib arm relative to the placebo arm at all on-study assessments. Mean greatest increases from baseline in pulse rate on treatment were 24.1 and 15.8 beats/min in the niraparib and placebo arms, respectively. Mean greatest increases from baseline in systolic blood pressure on treatment were 24.5 and 18.3 mmHg in the niraparib and placebo arms, respectively. Mean greatest increases from baseline in diastolic blood pressure on treatment were 16.5 and 11.6 mmHg in the niraparib and placebo arms, respectively.
Cardiac Electrophysiology The potential for QTc prolongation with niraparib was evaluated in a randomized, placebo-controlled trial in cancer patients (367 patients on niraparib and 179 patients on placebo). No large changes in the mean QTc interval (>20 ms) were detected in the trial following the treatment of niraparib 300 mg once daily.

Mechanism of action

Niraparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP-1 and PARP-2, which play a role in DNA repair. In vitro studies have shown that niraparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes resulting in DNA damage, apoptosis and cell death. Increased niraparib-induced cytotoxicity was observed in tumor cell lines with or without deficiencies in BRCA1/2. Niraparib decreased tumor growth in mouse xenograft models of human cancer cell lines with deficiencies in BRCA1/2 and in human patient-derived xenograft tumor models with homologous recombination deficiency that had either mutated or wild type BRCA1/2.

TargetActionsOrganism
APoly [ADP-ribose] polymerase 1
antagonist
Humans
APoly [ADP-ribose] polymerase 2
antagonist
Humans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

The absolute bioavailability of niraparib is approximately 73%. Following oral administration of niraparib, peak plasma concentration, Cmax, is reached within 3 hours. Concomitant administration of a high fat meal (800-1,000 calories with approximately 50% of total caloric content of the meal from fat) did not significantly affect the pharmacokinetics of niraparib.
Following a single-dose administration of 300 mg niraparib, the mean (±SD) peak plasma concentration (Cmax) was 804 (± 403) ng/mL. The systemic exposures (Cmax and AUC) of niraparib increased in a dose proportional manner with daily doses ranging 30 mg (0.1 times the approved recommended dosage) to 400 mg (1.3 times the approved recommended dosage). The accumulation ratio of niraparib exposure following 21 days of repeated daily doses was approximately 2 fold for doses ranging from 30 mg to 400 mg.

Volume of distribution

The average (±SD) apparent volume of distribution (Vd/F) was 1220 (±1114) L.

Protein binding

Niraparib is 83.0% bound to human plasma proteins.

Metabolism

Niraparib is metabolized primarily by carboxylesterases (CEs) to form a major inactive metabolite, which subsequently undergoes glucuronidation.

Route of elimination

Following administration of a single oral 300 mg dose of radio-labeled niraparib, the average percent recovery of the administered dose over 21 days was 47.5% (range 33.4% to 60.2%) in urine, and 38.8% (range 28.3% to 47.0%) in feces.

Half life

Following multiple daily doses of 300 mg niraparib, the mean half-life (t1/2) is 36 hours.

Clearance

the apparent total clearance (CL/F) of niraparib was 16.2 L/h in cancer patients.

Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Darbepoetin alfaThe risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Niraparib.
ErythropoietinThe risk or severity of Thrombosis can be increased when Erythropoietin is combined with Niraparib.
Methoxy polyethylene glycol-epoetin betaThe risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Niraparib.
PeginesatideThe risk or severity of Thrombosis can be increased when Peginesatide is combined with Niraparib.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Chen A: PARP inhibitors: its role in treatment of cancer. Chin J Cancer. 2011 Jul;30(7):463-71. doi: 10.5732/cjc.011.10111. [PubMed:21718592]
  2. FDA approval [Link]
  3. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors [Link]
  4. FDA label [Link]
External Links
PubChem Compound
24958200
PubChem Substance
347828142
ChemSpider
24531930
BindingDB
50316226
ChEMBL
CHEMBL1094636
PharmGKB
PA166131610
HET
3JD
Wikipedia
Niraparib
ATC Codes
L01XX54 — Niraparib
PDB Entries
4r6e

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingOtherAdvanced Solid Tumors1
1Active Not RecruitingTreatmentBRCA1 Gene Mutation / Brca2 Gene Mutation / Human Epidermal Growth Factor 2 Negative Carcinoma of Breast1
1Active Not RecruitingTreatmentCancer, Advanced / Lung Cancer Non-Small Cell Cancer (NSCLC) / Metastatic Cancers / Non Small Cell Lung Cancer Metastatic / Non Small Cell Lung Cancer Stage IIIB / Tumors, Solid1
1CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / T-cell-prolymphocytic Leukemia / Tumors, Solid1
1CompletedTreatmentGlioblastoma Multiforme (GBM) / Melanoma / Recurrence of Solid Tumor1
1CompletedTreatmentMalignancies1
1CompletedTreatmentOvarian Cancer1
1CompletedTreatmentProstatic Neoplasms1
1Not Yet RecruitingTreatmentMalignant Neoplasm of Stomach1
1Not Yet RecruitingTreatmentOvarian Cancer / Resistant BRCA Wild-Type Ovarian Cancer1
1Not Yet RecruitingTreatmentRecurrent Ovarian Cancer1
1RecruitingTreatmentBreast Cancer / Ovarian Cancer1
1RecruitingTreatmentDeleterious BRCA1 Gene Mutation / Deleterious BRCA2 Gene Mutation / Endometrial Adenocarcinomas / High Grade Ovarian Serous Adenocarcinoma / Platinum-Resistant Ovarian Carcinoma / Primary Peritoneal High Grade Serous Adenocarcinoma / Progressive Disease / Recurrent Endometrial Carcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma1
1RecruitingTreatmentEwing's Sarcoma (ES)1
1RecruitingTreatmentHepatic Impairment / Tumors, Solid1
1RecruitingTreatmentHomologous Recombination Deficiency / Solid Tumor, Adult1
1RecruitingTreatmentHormone-Refractory Prostate Cancer / Prostate Carcinoma Metastatic to the Bone / Stage IV Prostate Adenocarcinoma1
1RecruitingTreatmentLung Cancers1
1RecruitingTreatmentOvarian Cancer2
1RecruitingTreatmentResidual Disease / Triple Negative Breast Cancer (TNBC)1
1RecruitingTreatmentTumors, Solid1
1TerminatedTreatmentCancer: Solid Tumors1
1TerminatedTreatmentMetastatic Hormone Refractory Prostate Cancer1
1TerminatedTreatmentNeoplasms / Tumors, Solid1
1TerminatedTreatmentOvarian Cancer1
1, 2Active Not RecruitingTreatmentAdvanced Breast Cancer / Breast Cancer / Fallopian Tube Cancer / Malignant Peritoneal Neoplasm / Metastatic Breast Cancer / Ovarian Cancer / Stage IV Breast Cancer / Triple Negative Breast Cancer (TNBC)1
1, 2Active Not RecruitingTreatmentOvarian Cancer1
1, 2Not Yet RecruitingTreatmentExtensive Stage Lung Small Cell Carcinoma / Stage III Lung Cancer AJCC v8 / Stage IIIA Lung Cancer AJCC v8 / Stage IIIB Lung Cancer AJCC v8 / Stage IIIC Lung Cancer AJCC v8 / Stage IV Lung Cancer AJCC v8 / Stage IVA Lung Cancer AJCC v8 / Stage IVB Lung Cancer AJCC v81
1, 2Not Yet RecruitingTreatmentProstate Cancer1
1, 2RecruitingOtherUrothelial Cancer1
1, 2RecruitingTreatmentAdenocarcinoma of the Pancreas1
1, 2RecruitingTreatmentHER2 Positive Breast Carcinoma / Metastatic Breast Cancer1
1, 2RecruitingTreatmentMetastatic Carcinoma of the Cervix1
1, 2RecruitingTreatmentProstatic Neoplasms, Castration-Resistant1
1, 2RecruitingTreatmentTransitional Cell Carcinoma1
2Active Not RecruitingTreatmentFallopian Tube Cancer / Ovarian Cancer / Primary Peritoneal Cancer2
2Active Not RecruitingTreatmentFallopian Tube Cancer / Ovarian Cancer / Primary Peritoneal Carcinoma1
2Active Not RecruitingTreatmentNeoplasms, Lung1
2Active Not RecruitingTreatmentOvarian Cancer2
2Not Yet RecruitingTreatmentATM Gene Mutation / BRCA1 Gene Mutation / Brca2 Gene Mutation / BRIP1 Gene Mutation / CDK12 Gene Mutation / CHEK1 Gene Mutation / CHEK2 Gene Mutation / DNA Damage Response Gene Mutation / DNA Repair Gene Mutation / FANCA Gene Mutation / FANCD2 Gene Mutation / FANCL Gene Mutation / GEN1 Gene Mutation / NBN Gene Mutation / Prostate Cancer / RAD51 Gene Mutation / RAD51C Gene Mutation1
2Not Yet RecruitingTreatmentFallopian Tube Cancer / Ovarian Cancer / Primary Peritoneal Carcinoma1
2Not Yet RecruitingTreatmentOvarian Cancer1
2Not Yet RecruitingTreatmentProgressive Cervix Cancer / Recurrent Cervix Cancer1
2Not Yet RecruitingTreatmentTumors, Solid1
2RecruitingTreatmentAdenocarcinoma, Prostate / Stage IIC Prostate Cancer AJCC v8 / Stage III Prostate Cancer AJCC v8 / Stage IIIA Prostate Cancer AJCC v8 / Stage IIIB Prostate Cancer AJCC v8 / Stage IIIC Prostate Cancer AJCC v8 / Stage IVA Prostate Cancer AJCC v81
2RecruitingTreatmentAdenocarcinomas / Esophageal Cancers / Malignant Neoplasm of Stomach1
2RecruitingTreatmentAdvanced Microsatellite Stable Colorectal Carcinoma / Metastatic Microsatellite Stable Colorectal Carcinoma / Microsatellite Stable / MSI-H Colorectal Cancer / RAS Wild Type / Stage IV Colorectal Cancer AJCC v81
2RecruitingTreatmentBreast Cancer1
2RecruitingTreatmentCarcinoma, Squamous Cell of Head and Neck1
2RecruitingTreatmentCholangiocarcinomas / Mesothelioma / Renal Cell Adenocarcinoma / Uveal Melanoma1
2RecruitingTreatmentEndometrial Cancer1
2RecruitingTreatmentEndometrial Cancer / Endometrial Carcinoma / Papillary serous endometrial carcinoma / Uterine Serous Carcinoma1
2RecruitingTreatmentFallopian Tube Cancer / Ovarian Cancer / Primary Peritoneal Carcinoma1
2RecruitingTreatmentFallopian Tube Cancer / Primary Peritoneal Carcinoma / Recurrent Ovarian Cancer1
2RecruitingTreatmentGBM / Glioblastomas / Recurrent Glioblastoma1
2RecruitingTreatmentMalignant Neoplasm of Pancreas2
2RecruitingTreatmentPlatinum-resistant Ovarian Cancer1
2RecruitingTreatmentProstatic Neoplasms1
2RecruitingTreatmentTransitional Cell Carcinoma1
2WithdrawnTreatmentMalignant Lymphomas / Mantle-Cell1
2, 3Not Yet RecruitingTreatmentEndometrial Carcinosarcoma / Ovarian Carcinosarcoma1
3Active Not RecruitingTreatmentBRCA1 Gene Mutation / Brca2 Gene Mutation / Carcinoma of Breast / Human Epidermal Growth Factor 2 Negative Carcinoma of Breast1
3Active Not RecruitingTreatmentOvarian Cancer1
3Active Not RecruitingTreatmentPlatinum Sensitive Ovarian Cancer1
3Not Yet RecruitingTreatmentOvarian Cancer1
3RecruitingTreatmentMetastatic Hormone Refractory Prostate Cancer1
3RecruitingTreatmentOvarian Cancer1
3RecruitingTreatmentRecurrent Ovarian Carcinoma1
4RecruitingTreatmentOvarian Cancer1
Not AvailableAvailableNot AvailableRecurrent Ovarian Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral100 mg
CapsuleOral100 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8859562No2014-10-142031-08-04Us
US8143241No2012-03-272027-08-12Us
US8071579No2011-12-062027-08-12Us
US8071623No2011-12-062030-03-22Us
US8436185No2013-05-072029-04-24Us
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0149 mg/mLALOGPS
logP2.45ALOGPS
logP2.47ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)14.03ChemAxon
pKa (Strongest Basic)10.1ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area72.94 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity94.92 m3·mol-1ChemAxon
Polarizability36.41 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpiperidines. These are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Piperidines
Sub Class
Phenylpiperidines
Direct Parent
Phenylpiperidines
Alternative Parents
Phenylpyrazoles / Indazoles / Aralkylamines / Benzene and substituted derivatives / Heteroaromatic compounds / Primary carboxylic acid amides / Amino acids and derivatives / Dialkylamines / Azacyclic compounds / Organooxygen compounds
show 2 more
Substituents
Phenylpiperidine / Phenylpyrazole / Benzopyrazole / Indazole / Aralkylamine / Benzenoid / Monocyclic benzene moiety / Heteroaromatic compound / Pyrazole / Azole
show 15 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Zinc ion binding
Specific Function
Involved in the base excision repair (BER) pathway, by catalyzing the poly(ADP-ribosyl)ation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. This ...
Gene Name
PARP1
Uniprot ID
P09874
Uniprot Name
Poly [ADP-ribose] polymerase 1
Molecular Weight
113082.945 Da
References
  1. PARP inhibitor, MK-4827, shows anti-tumor activity in first trial in humans [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Nad+ adp-ribosyltransferase activity
Specific Function
Involved in the base excision repair (BER) pathway, by catalyzing the poly(ADP-ribosyl)ation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. This ...
Gene Name
PARP2
Uniprot ID
Q9UGN5
Uniprot Name
Poly [ADP-ribose] polymerase 2
Molecular Weight
66205.31 Da
References
  1. PARP inhibitor, MK-4827, shows anti-tumor activity in first trial in humans [Link]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Substrate
General Function
Carboxylic ester hydrolase activity
Specific Function
Not Available
Gene Name
CES1A1a
Uniprot ID
Q6LAP9
Uniprot Name
Carboxylesterase
Molecular Weight
1908.25 Da
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Substrate
General Function
Receptor binding
Specific Function
Plays an important role in the degradation of dermatan and keratan sulfates.
Gene Name
GUSB
Uniprot ID
P08236
Uniprot Name
Beta-glucuronidase
Molecular Weight
74731.46 Da

Drug created on October 20, 2016 14:48 / Updated on January 20, 2020 03:04